SCHEMBL10186676

SCHEMBL10186676

CCCc1ccc(Cl)c(CNC(C)C)c1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
KCNH2 Q12809 2/20 0.38
TMEM97 Q5BJF2 2/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
SIGMAR1 Q99720 2/20 0.36
GAA P10253 1/20 0.35
ACACB O00763 2/20 0.35
PNMT P11086 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667234 0.83 NR3C1 (0.43) LMNAKCNH2TMEM97POLBMEN1
SCHEMBL10186666 0.81 SLC6A4 (0.51) KCNH2CNR1CNR2SIGMAR1PNMT
SCHEMBL10186685 0.81 HTR1A (0.42) POLBMEN1KMT2ACNR1CNR2
SCHEMBL7637395 0.79 CNR1 (0.45) MEN1KMT2ACNR1CNR2SIGMAR1
SCHEMBL14438275 0.78 MEN1 (0.43) LMNAKCNH2POLBMEN1KMT2A
SCHEMBL10186681 0.76 POLB (0.45) POLBMEN1KMT2AGAA
SCHEMBL10186620 0.75 POLB (0.41) KCNH2POLBMEN1KMT2ASIGMAR1
SCHEMBL16870109 0.75 SIGMAR1 (0.45) KCNH2TMEM97KMT2ASIGMAR1ACACB
SCHEMBL15979353 0.75 KCNH2 (0.43) LMNAKCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL321307 0.74 CNR1 (0.46) POLBCNR1CNR2SIGMAR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046293-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046293-A1 RENIN INHIBITORS REN, ACE, AGTR1 LMNA 1559/4885KCNH2 1215/4885TMEM97 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.